RxDoctor Payments Data

Sana Siddiqi, MD

Neurology · Chambersburg, PANPI 1689016198

Payments from drug & device makers

$28,430in general payments, 2019–2025

Across 35 payments — averaging $812.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$26K
  • Pfizer$2K
  • Novus Surgical Consultants$876
  • Lundbeck LLC$167
  • Axsome Therapeutics, Inc.$19

What the payments were for

  • Consulting fees$1,5255%
  • Speaking & faculty fees$24,85087%
  • Travel & lodging$1,4375%
  • Food & beverage$6182%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie25$25,840
Pfizer2$1,528
Novus Surgical Consultants5$876
Lundbeck LLC2$167
Axsome Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,430 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,510
Medicare patients
100
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant106$165,307
QuliptaAtogepant97$130,708
Nurtec OdtRimegepant Sulfate66$113,003
Emgality PenGalcanezumab-Gnlm115$93,533
BotoxOnabotulinumtoxina31$40,062
Aimovig AutoinjectorErenumab-Aooe48$35,125
Ajovy SyringeFremanezumab-Vfrm41$29,317
ReyvowLasmiditan Succinate18$15,877
XareltoRivaroxaban12$6,351
Carbamazepine ErCarbamazepine45$3,892
Levetiracetam99$3,336
Gabapentin122$2,655
Topiramate261$2,542
Pregabalin60$1,678
Oxcarbazepine44$1,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$25,840$336,078234 claims
PfizerNurtec Odt$1,528$113,00366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →